J-147
curcumin-derived neuroprotective
J-147 (curcumin-derived neuroprotective) is a cognitive & mood research compound. Derived from curcumin but a distinct molecule with far better brain penetration. Its target was identified as mitochondrial ATP synthase — modestly inhibiting it triggers an adaptive stress response that raises mitochondrial calcium buffering and downstream NGF and BDNF. It was selected in ageing-brain models rather than amyloid models, which is why its profile reads differently from the Alzheimer's drugs it sits beside.
J-147 quick facts
| Route | Oral |
| Frequency | 1x Daily |
| Half-life | Not well characterised in public data |
| Forms | Oral |
| Evidence level | Preclinical (extensive rodent, Salk Institute); early human safety work |
One of the few nootropic-adjacent compounds with a clearly identified molecular target. The rodent data is strong and the human data barely exists — that gap is the whole story here. A phase 1 finished in 2020 and never published its results, so no human dose has ever been reported. The 10-20mg shown is the vendor's capsule size; it happens to land below the ~57mg you get scaling the mouse dose, which is the safer direction, but neither number was established in a person.
How J-147 works
Derived from curcumin but a distinct molecule with far better brain penetration. Its target was identified as mitochondrial ATP synthase — modestly inhibiting it triggers an adaptive stress response that raises mitochondrial calcium buffering and downstream NGF and BDNF. It was selected in ageing-brain models rather than amyloid models, which is why its profile reads differently from the Alzheimer's drugs it sits beside.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
✅ Clinically validated
- A phase 1 single-ascending-dose study in healthy volunteers (NCT03838185) completed in 2020 and never published its results. A human dose was therefore measured and not reported. There is nothing to cite. The 10-20mg on this page is the vendor's capsule size — it lands below the ~57mg you get by scaling the rodent dose, which is the conservative direction, but neither figure was established in a person.
📊 Correlative data
- Curcumin itself has a long record of poor oral bioavailability and poor brain penetration — the problem J-147 was built to solve. Read the parent compound's disappointing trial history as context for why a derivative was needed, not as evidence the derivative works.
🧪 Theoretical / extrapolated
- Its molecular target was identified as mitochondrial ATP synthase. Modestly inhibiting it triggers an adaptive stress response that raises mitochondrial calcium buffering and downstream NGF and BDNF — a hormetic mechanism rather than a blocking one.
- It was selected in ageing-brain models rather than amyloid models, which is why its preclinical profile reads differently from the Alzheimer's drugs it sits beside. Extensive rodent data; almost no human data.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
J-147 — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- Its identified target is mitochondrial ATP synthase, and the mechanism is *modest inhibition* — the benefit is the adaptive stress response that inhibition provokes, not a boost. That is hormesis, and hormesis has a specific shape worth understanding before dosing: the dose that helps and the dose that harms are the same mechanism at different magnitudes. More is not more neuroprotective, and there is no reason to expect the curve to be a ramp.
- ATP synthase is not a brain-specific enzyme. It is in every mitochondrion you own. A molecule that inhibits it will reach heart, liver and skeletal muscle as well, and the ageing-brain models it was selected in were never asked what it did to those tissues.
- Its parent chemistry is curcumin, which is a genuine inhibitor of several CYP enzymes and of platelet aggregation. Whether J-147 retained either property is unknown — but they are the properties to suspect first, because they are the ones the scaffold came with.
What has actually been reported
- Essentially nothing in humans. A phase 1 completed in 2020 and its results were never published — which is the least reassuring form of 'there was a trial', because it means human safety data exists and nobody outside the sponsor can read it.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Do not treat 'more' as 'more neuroprotective'. An inhibitor working through hormesis is the specific case where escalating the dose can cross from the adaptive response into the thing it was adapting to.
- Do not stack it with other mitochondrial inhibitors or uncouplers. Two compounds acting on the electron transport chain is not additive benefit, it is additive inhibition, and the Vault has several other cards that belong to that category.
- Stop it before surgery, on the standard curcuminoid precaution — the cost of doing so is nothing and the question is unresolved.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- A liver panel, on the reasoning that a systemically distributed mitochondrial inhibitor reaches the liver too.
- A full blood count if you are on anything affecting platelets, for the curcuminoid question above.
Don't run this if
- You take an anticoagulant or antiplatelet, or have surgery scheduled, until the curcumin-family platelet question is settled. It currently is not.
- You take a narrow-therapeutic-index drug cleared by CYP3A4, where a modest inhibition would matter.
The honest unknown
- The contents of that unpublished phase 1. The entire safety position on this compound would change if those results appeared, in either direction — which is itself the reason to treat the current position as provisional rather than reassuring.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get J-147
Buy J-147 at Disguised Alpha →J-147 — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What J-147 moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for J-147 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
Get the complete breakdown for J-147 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside J-147
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anaemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 102 markers A–Z
J-147 — frequently asked questions
What is J-147?
J-147 (curcumin-derived neuroprotective) is a cognitive & mood research compound. Derived from curcumin but a distinct molecule with far better brain penetration. Its target was identified as mitochondrial ATP synthase — modestly inhibiting it triggers an adaptive stress response that raises mitochondrial calcium buffering and downstream NGF and BDNF. It was selected in ageing-brain models rather than amyloid models, which is why its profile reads differently from the Alzheimer's drugs it sits beside.
Where can I find J-147 dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full J-147 protocol are available to members inside the Academy. This public page covers what J-147 is, how it works and the evidence.
What is the half-life of J-147?
J-147 has an approximate half-life of Not well characterised in public data, which is part of what determines how often it's dosed.
What's the evidence behind J-147?
Current evidence level: Preclinical (extensive rodent, Salk Institute); early human safety work. J-147 is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact J-147 protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →